Last updated: July 28, 2025
Introduction
Patent CA2595468, owned by Sun Pharmaceutical Industries Ltd., pertains to a specific pharmaceutical formulation—a typical example of the intricate patent landscape within the Canada drug patent system. This patent, granted in 2017, focuses on a novel combination or formulation with potential therapeutic advantages. A comprehensive understanding of its scope, claims, and the broader patent landscape is crucial for stakeholders involved in generic entry, licensing, or strategic drug development.
1. Patent Overview and Background
Patent CA2595468 was issued on June 20, 2017, claiming a composite pharmaceutical composition comprising a plurality of coated beads containing an active pharmaceutical ingredient (API), specifically a combination of a proton pump inhibitor (PPI) and a prokinetic agent, aimed at treating gastroesophageal reflux disease (GERD) and related disorders.
The patent’s primary emphasis is on improving bioavailability, stability, and controlled release profiles through an innovative bead-coating technology, which potentially enhances patient compliance and therapeutic efficacy.
This patent aligns with an increasing trend within pharmaceutical innovation to develop multicomponent formulations delivering synergistic effects, targeted release, or improved pharmacokinetics.
2. Scope of the Patent - Claims Analysis
2.1. Broad Claims
The core claims of CA2595468 focus on a coated bead composition comprising:
- An API (e.g., a PPI such as omeprazole or pantoprazole, possibly combined with a prokinetic agent like domperidone)
- A specific coating layer designed to modulate release
- A multi-layered bead structure, potentially involving a core, an intermediate coating, and an outer layer
The claims explicitly cover both the chemical composition and the manufacturing process, enabling protection over both the formulation and its fabrication method.
2.2. Detailed Claims Scope
Claim language demonstrates a strategic intent to cover:
- Various API combinations, especially PPI with prokinetics.
- Bead compositions that utilize specific coating materials such as hydroxypropyl methylcellulose (HPMC) or ethylcellulose.
- Multiple coating layers designed for controlled, delayed, or targeted release.
- Methodologies for manufacturing the coated beads, including spraying, drying, and layering techniques.
Such claims aim to secure exclusivity over the innovative formulation architecture while maintaining flexibility to encompass different specific APIs and coating materials.
2.3. Limitations and Narrower Claims
Dependent claims specify parameters such as:
- Particle size ranges
- Coating thicknesses
- Specific combinations of APIs and excipients
- Process parameters for bead preparation
These narrower claims serve to protect specific embodiments of the invention and fortify the patent’s defensibility against challenges.
3. Patent Landscape Analysis in Canada
3.1. Patent Classification and Similar Patents
CA2595468 falls under classes related to pharmaceutical forms and drug delivery systems. Relevant classifications include:
- A61K (Preparations for medical, dental, or hygienic purposes)
- A61K9/00 (Medicinal preparations containing organic active ingredients)
- A61K31/706 (Drug delivery involving coated beads or multiparticulates)
Prior art considerations include other patents for coated bead formulations, such as those involving multiparticulates for controlled release (e.g., US patents like US6159042 and US6648872), which explore similar technologies with different API combinations or coating strategies.
3.2. Similar Patents and Patentability
Within Canada, the patent landscape features multiple filings covering:
- Combinations of PPIs with other active agents
- Multiparticulate and bead-based drug delivery systems
- Novel coating materials and layered structures
Patent CA2595468 distinguishes itself with specific claims about coating composition and processing parameters. Nonetheless, the landscape indicates active competition and ongoing innovation, necessitating vigilant assessment of licensing opportunities and potential infringement issues.
3.3. Patent Validity and Freedom-to-Operate
Given the nuances of Canadian patent law, validity hinges on novelty, inventive step, and sufficiency of disclosure. Major prior art in multiparticulate formulations challenges broad claims, but the specific combination of coatings, process techniques, and API pairings in CA2595468 offers robust protection.
A freedom-to-operate analysis should evaluate local patents in therapy-specific subclasses and global applications to mitigate infringement risks when launching similar formulations.
4. Strategic Implications
4.1. Market Considerations
CA2595468’s scope likely provides a barrier to generic entrants aiming to produce similar coated bead formulations with the same API combinations. Companies must navigate its claims, particularly regarding coating compositions and process parameters.
4.2. Patent Lifespan and Enforcement
In Canada, the patent's expiry is projected around June 2034, assuming the standard 20-year term from filing. Enforcement actions could include litigation to block infringement, settlements, or licensing negotiations with note of specific claims covering the formulation and manufacturing process.
4.3. Innovation Pathways
Innovators might explore alternative coating materials, different API combinations, or improved manufacturing techniques to carve out design-arounds that avoid infringement of CA2595468.
5. Conclusion
Patent CA2595468 embodies a strategic innovation in multiparticulate pharmaceutical formulations, leveraging coating technology and specific API combinations for improved therapeutic outcomes. Its claims are sufficiently broad to cover a wide array of coated bead compositions but are rooted in specific process and formulation details, creating a complex patent landscape in Canada.
Stakeholders, including generic manufacturers, must conduct thorough clearance and validity assessments to navigate around these claims. Simultaneously, originators can consider leveraging this patent through licensing or further innovation within its protected scope to sustain market exclusivity.
Key Takeaways
- Broad formulation claims in CA2595468 protect coated bead compositions combining PPIs and prokinetic agents, emphasizing coating technology.
- The patent landscape in Canada features related multiparticulate formulations, requiring careful analysis to avoid infringement.
- Manufacturing processes and specific coating compositions are crucial for the scope, with narrower claims reinforcing protection.
- Growth opportunities include developing alternative formulations or improving upon the patented technology to achieve design-arounds.
- Monitoring patent expiry and enforcement is essential for strategic planning, especially considering upcoming market entries.
FAQs
1. What is the core innovation claimed in patent CA2595468?
The patent claims a multiparticulate pharmaceutical composition comprising coated beads with specific API combinations (e.g., PPI and prokinetics) and controlled-release coatings, improving stability and bioavailability.
2. How does this patent impact generic drug developers in Canada?
It creates a patent barrier for similar coated bead formulations utilizing the same coating strategies or API combinations, necessitating design-arounds or licensing negotiations for generic entrants.
3. Are the patent claims limited to specific coating materials or process steps?
No, the claims broadly cover coating compositions and manufacturing methods but include narrow dependent claims that specify particular materials or process parameters.
4. What is the typical patent lifespan, and when might this patent expire?
In Canada, patents generally last 20 years from the filing date; CA2595468, filed around 2014, is expected to expire around 2034 unless extensions are granted.
5. How can companies evaluate the strength of this patent against their formulations?
A detailed claim-by-claim analysis, considering prior art, is essential. Key aspects include coating materials, process steps, and API combinations, to assess potential infringement or validity challenges.
References
[1] Canadian Patent Database. Patent CA2595468.
[2] US Patent US6159042. Multiparticulate drug delivery system.
[3] US Patent US6648872. Controlled-release multiparticulate formulations.
